The Ministry of Health announces that the vaccine against the Coronavirus produced by Moderna has already arrived in Romania, only 14.000 doses have been received, they will be distributed throughout the country by the authorities to immunize the Romanians.
The Ministry of Health is waiting for more doses of the vaccine against the Coronavirus produced by Pfizer, but it will be quite difficult for them to arrive in our country because they are available in very limited quantities, which is also a problem for many other countries.
"The first tranche, of 14.000 doses of the Moderna vaccine, will arrive tomorrow at the National Institute for Medical-Military Research-Development "CANTACUZINO". The transport is provided by the producing company, and the vaccine doses will be brought to Bucharest by land.
The doses will be stored at the National Storage Center, and in the following period they will be distributed to the regional and vaccination centers.
The National Center for the Storage of Vaccines against COVID-19 within the "Cantacuzino" Institute is fully authorized and approved by the Romanian National Medicines and Medical Devices Authority - the national authority with competence in the field of medicine for human use. As a result of receiving authorization from ANMDMR, the National Institute of Medical-Military Research and Development "Cantacuzino" can carry out, as a wholesale distributor, holding, custody and delivery operations for medicines to which additional criteria apply such as: products in agreement with art. 806 of Law 95/2006 republished: immunological medicines, respectively products distributed in the "cold chain" (which require handling at low temperatures).
***
The recommendation for the Moderna vaccine is to administer it in two doses, at an interval of 28 days, for people over 18 years of age.
The two types of vaccines available in the EU are very similar. The effectiveness of the two vaccines is about the same. Pfyzer's BioNTech vaccine is 95% effective in preventing COVID-19, while Moderna's vaccine is 94,1% effective. For none of the vaccines, it is not yet possible to say the extent to which they also prevent asymptomatic SARS-CoV2 infection.
Both vaccines use technology based on messenger RNA. This type of vaccine teaches the body to generate antibodies needed to fight the virus. Antibodies are prepared to fight the real virus when the vaccinated person is exposed to SARS-CoV2 infection. The messenger RNA penetrates into human cells, where it transmits the information necessary for the production of its own viral proteins, against which, subsequently, antibodies will be developed. The fragments of messenger RNA are damaged by the enzymes of human cells within a period of up to 5-7 days and do not influence the cellular DNA in any way, considering that it does not enter the nucleus.
Long-term storage: at -20 degrees C Storage 2-8 degrees C: 30 days."
